1798-82-9

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyclopropylbenzoic acid is used as a key intermediate in the synthesis of Bruton's Tyrosine Kinase (BTK) inhibitors for the treatment of various B-cell malignancies, including chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and autoimmune diseases. Its unique structure contributes to the development of potent and selective BTK inhibitors, which play a crucial role in modulating the immune system and combating these diseases.

InChI:InChI=1/C10H10O2/c11-10(12)9-5-3-8(4-6-9)7-1-2-7/h3-7H,1-2H2,(H,11,12)

Upstream product

• 6921-45-5 1-(4-cyclopropylphenyl)ethanone 
• 1124-14-7 1-bromo-4-cyclopropylbenzene 
• 124-38-9 carbon dioxide 
• 544-92-3 copper(I) cyanide 
• 20034-50-8 4-cyclopropylbenzaldehyde 
• 6921-43-3 1-cyclopropyl-4-methyl-benzene 
• 19824-39-6 p-Cyclopropyl-styrol 
• 873-49-4 cyclopropylbenzene 
• 3158-71-2 4-cyclopropylaniline 
• 18620-02-5 (4-bromophenyl)magnesium bromide 
• 500-05-0 2H-pyran-2-one-5-carboxylic acid 
• 6746-94-7 Cyclopropylacetylene 
• 75-36-5 acetyl chloride 
• 1128-70-7 3-(4-bromo-phenyl)-4,5-dihydro-1H-pyrazole 

Downstream Products

• 1129-08-4 4-Cyclopropyl-benzoesaeure-amid 
• 1202053-87-9 N-(5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)-4-cyclopropylbenzamide 
• 1418128-50-3 4-[4-[3-(4-cyclopropyl-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1198088-28-6 4-(2-guanidinothiazol-4-yl)phenyl 4-cyclopropylbenzoate hydrobromide 
• 1198088-27-5 4-(2-bromoacetyl)phenyl 4-cyclopropylbenzoate 
• 1198088-26-4 4-acetylphenyl 4-cyclopropylbenzoate 

Relevant academic research and scientific papers

Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists

Obesity is a major clinical problem in the western world, and many molecular targets have been explored in the search for effective therapeutic agents. One of these, antagonism of the cannabinoid 1 (CB1) receptor, rose to prominence following reports demo

MYOSIN LIGHT CHAIN PHOSPHATASE INHIBITORS

Novel myosin light chain phosphatase inhibitors, compositions containing them, methods of making and using them, and methods of using fluorescent myosin light chain phosphatase inhibitors are described.

INHIBITORS OF STEAROYL-COA DESATURASE

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.

Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3

A class of 3,5-diphenyl-1,2,4-oxadiazole based compounds have been identified as potent sphingosine-1-phosphate-1 (S1P1) receptor agonists with minimal affinity for the S1P2 and S1P3 receptor subtypes. Analogue 26 (S1P1 IC50 = 0.6 nM) has an excellent pharmacokinetics profile in the rat and dog and is efficacious in a rat skin transplant model, indicating that S1P3 receptor agonism is not a component of immunosuppressive efficacy.

SYNTHESIS OF p-ALKYLBENZOIC ACIDS BY ONE-ELECTRON OXIDATION OF p-ALKYLTOLUENES. MINDO/3 CALCULATIONS OF p-ALKYLTOLUENES AND THEIR RADICAL CATIONS

Calculations for p-cymene, p-cyclopropyltoluene, and their radical cations were undertaken by the LCAO-MO SCF method in the MINDO/3 valence approximation.It was shown that the radical-cations are stabilized by ?,? conjugation of the methyl group.The radical-cations are hardly stabilized at all by the p-sec-alkyl radicals.This leads to the result that the oxidation of p-sec-alkyltoluenes and p-cycloalkyltoluenes through electron transfer only takes place at the methyl group with the formation of p-sec-alkyl- and p-cycloalkylbenzoic acids.